DexCom (DXCM) PT Lowered to $62 at BMO Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. SPY
2. PCVX
3. NVDA
4. KLC
5. TSLA
6. PTC
7. CME
8. USO
9. AMD
10. EVTL

Go back to DexCom (DXCM) PT Lowered to $62 at BMO Capital

DexCom (DXCM) PT Lowered to $57 at Leerink Partners

September 29, 2017 6:50 AM EDT

Leerink Partners analyst Danielle Antalffy lowered her price target on DexCom (NASDAQ: DXCM) to $57.00 (from $85.00) while maintaining an Outperform rating.

Despite increased competition, Antalffy said a pricing sensitivity analysis shows a path to share upside.

... More

DexCom (DXCM) PT Lowered to $70 at Stephens

September 28, 2017 6:13 AM EDT

Stephens lowered its price target on DexCom (NASDAQ: DXCM) to $70.00 (from $83.00) while maintaining a Overweight rating.

Analyst Chris Cooley sees the CY 2018 outlook as challenging but expects clearance of G6 and user preference for accuracy and functional CGM data to drive a re-accelerated top-line growth as H2 2018 approaches.

... More

Raymond James Downgrades DexCom (DXCM) to Market Perform

September 28, 2017 5:05 AM EDT

Raymond James downgraded DexCom (NASDAQ: DXCM) from Outperform to Market Perform.

Analyst Jayson Bedford removes his $80.00 price target.

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $67.47 yesterday.

... More

DexCom (DXCM) PT Lowered to $60 at Barclays

September 28, 2017 5:01 AM EDT

Barclays lowered its price target on DexCom (NASDAQ: DXCM) to $60.00 (from $76.00) while maintaining a Equalweight rating.

Analyst Matt Taylor keeps a positive view on the company noting potential to produce exciting developments citing G6 sensors and collaborations with Verily/PODD that... More

DexCom (DXCM) PT Lowered to $64 at Cowen

September 28, 2017 4:58 AM EDT

Cowen lowered its price target on DexCom (NASDAQ: DXCM) to $64.00 (from $90.00) while maintaining a Outperform rating.

Analyst Doug Schenkel says comments from Abbott (NYSE: ABT) on pricing after receiving approval for Libre creates a... More

DexCom (DXCM) PT Lowered to $69 at Canaccord Genuity

September 28, 2017 3:24 AM EDT

Canaccord Genuity lowered its price target on DexCom (NASDAQ: DXCM) to $69.00 (from $90.00) while maintaining a Buy rating.

Analyst Kyle Rose remains buy-rated noting that estimates are now reset. The analyst reduces his forward growth profile estimates by 10% for 2018, 12% for 2019 and 14% for... More

JPMorgan Downgrades DexCom (DXCM) to Neutral

September 28, 2017 3:06 AM EDT

JPMorgan downgraded DexCom (NASDAQ: DXCM) from Overweight to Neutral with a price target of $71.00 (from $93.00).

Analyst Mike Weinstein says the Libre label and aggressive pricing strategy puts the company at risk although he continues to still see positives.

FY 2018 EPS estimate falls from... More

DexCom (DXCM) Weakens After FDA Approves Abbott's (ABT) Continuous Glucose Monitoring System

September 27, 2017 5:38 PM EDT

Weakness in DexCom (NASDAQ: DXCM) after the market close on Wednesday was tied to news the FDA approved Abbott's (NYSE: ABT) continuous glucose monitoring system for adults not requiring blood sample calibration.

Shares of DexCom traded lower by 13%.

... More